Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 4,99 € (+1060,47%). La mediana è 4,99 € (+1060,47%).
| Acquista |
4 |
| Mantieni |
3 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Cresco Labs strengthens presence in Pennsylvania with purchase of PharmaCann for $50 million
Cresco Labs has acquired PharmaCann Penn for $50 million, gaining nine operational medical marijuana dispensaries in Pennsylvania. The payment was made in cash and via a seller note on a debt- and cash-free basis with a normalized target working capital level. Cresco expects the transaction to boost revenue, margins and cash flow and now operates in the state as both a retail and wholesale operator, running dispensaries under the Sunnyside brand and maintaining cultivation and wholesale activities. » Altro su de.investing.com
Cresco Labs beats Q2 expectations, but stock remains under pressure
Cresco Labs reported Q2 2026 revenue of $173.34 million and adjusted EPS of -$0.01, with both metrics topping analyst expectations. Adjusted EBITDA rose to $40 million (23% margin) and adjusted gross profit was $89 million (52% margin), while operating cash flow amounted to $15 million. The stock is trading near its 52-week low as investors weigh continued negative earnings, a only flat outlook for Q3 (around $173 million in revenue) and persistent pressures in the cannabis sector. Management sees growth potential in Pennsylvania, Ohio and Kentucky and a positive impact from possible federal reform, but warns of risks from competition, pricing pressure and regulatory uncertainty. » Altro su de.investing.com
Cresco Labs: analysts expect smaller quarterly loss on declining revenue on May 8
Cresco Labs will report results for the quarter ended March 31, 2026, on May 8, 2026. Four analysts on average estimate a loss of -0.023 USD per share (prior year -0.060 CAD), and six analysts forecast revenue of about 148.9 million USD (prior year 237.8 million CAD). For the current fiscal year, median analyst expectations are a loss of -0.075 USD per share and revenue of about 620.8 million USD (prior year 916.4 million CAD). » Altro su finanzen.net
Cresco Labs launches at-the-market stock program for around US$100 million
Cresco Labs has established an at-the-market (ATM) program to permit the sale of subordinate voting shares totaling up to approximately US$100 million. A distribution agreement has been entered with Haywood Securities; no shares have been issued yet. Net proceeds are intended primarily for general corporate purposes and potential acquisitions. Sales will occur on the Canadian Securities Exchange and are not registered for a U.S. public offering. » Altro su de.investing.com
Cresco Labs sells California business as part of strategic realignment
Cresco Labs has announced the sale of its operations in California to strengthen its balance sheet and cash flow, and to focus on higher-margin core markets. CEO Charlie Bachtell cited structural challenges and price pressure in the California market as reasons for the withdrawal. Analysts see uncertain short-term growth prospects, while the company continues to distribute its premium brand FloraCal in the US. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 152,54 Mln | 8,55% |
| Utile lordo | 70,17 Mln | 3,77% |
| Utile netto | -10,98 Mln | 24,42% |
| EBITDA | 9,14 Mln | 46,04% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 156,67 Mln € |
Numero di azioni | 361,07 Mln |
Massimo/minimo a 52 settimane | 2,09 € - 0,42 € |
| Dividendi | No |
Beta | 1,72 |
Rapporto P/E | -1,67 |
Rapporto PEG | 0,01 |
Rapporto P/B | 0,51 |
Rapporto P/S | 0,26 |
Profilo aziendale
Cresco Labs Inc., insieme alle sue controllate, coltiva, produce e vende prodotti a base di cannabis ad uso ricreativo e medicinale negli Stati Uniti. Offre cannabis in fiori, penne da svapo, live resin, penne monouso ed estratti con il marchio Cresco; cartucce da svapo, penne da svapo, fiori, popcorn, shake, pre-roll, shorties e concentrati con il marchio High Supply; svapi e gummy con il marchio Good News; svapi e edibili con il marchio Wonder Wellness Co; e tinture, capsule, unguenti e oli sublinguali con il marchio Remedi, nonché prodotti a base di cannabis con il marchio Reserve. La società offre inoltre fiori di cannabis con il marchio FloraCal; e confetti al cioccolato e al toffee, gummy alla frutta, caramelle dure e taffy con il marchio Mindy's Edibles, oltre a concedere in licenza il marchio Kiva, che produce edibili infusi di cannabis, tra cui confetti al cioccolato, gummy, mentine e crostatine. Inoltre, la società offre edibili infusi di cannabis con il marchio Sunnyside. Al 27 gennaio 2022 possedeva e gestiva 48 dispensari. La società è stata costituita nel 1990 ed ha sede a Chicago, Illinois.
| Nome | Cresco Labs |
| CEO | Charles Bachtell |
| Sede centrale | Chicago,
il Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 03/12/2018 |
| Dipendenti | 2900 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Cnq | CL.CN |
Pnk | CRLBF |
Frankfurt | 6CQ.F |
Düsseldorf | 6CQ.DU |
München | 6CQ.MU |